Apollomics (APLM) Cash & Equivalents (2020 - 2025)

Apollomics (APLM) has reported Cash & Equivalents for 6 consecutive years, with $3.3 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents fell 66.46% year-over-year to $3.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (down 66.46% YoY) and the FY2025 annual result came in at $3.3 million, down 66.46% from the prior year.
• Cash & Equivalents advanced to $3.3 million in Q4 2025 per APLM's latest filing, from $2.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for APLM reached as high as $50.7 million in Q2 2022 and fell as low as $2.1 million in Q2 2025.
• A 5-year average of $20.9 million and a median of $25.3 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents slumped 95.04% — and 2022, when it surged 403.78%.
• Year by year, Cash & Equivalents stood at $6.5 million in 2021, then jumped by 403.78% to $32.7 million in 2022, then fell by 1.89% to $32.1 million in 2023, then sank by 69.53% to $9.8 million in 2024, then sank by 66.46% to $3.3 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.3 million, $2.1 million, and $9.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.